Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2012

View Archived Issues

Novel GlyT1 inhibitors developed

Canadian study assesses involvement of neuroinflammation in healthy aging humans

Agenus and GSK expand license agreement for vaccine adjuvant

FDA clears IND application for phase III trial of melanoma vaccine

Phase III SAR-1118 trial completes enrollment

Palatin Technologies completes enrollment in phase IIb bremelanotide trial

Bayer HealthCare obtains new product approval

Isis launches phase I trial of first-generation antisense drug

Novel candidate schizophrenia therapies patented by Takeda

RaQualia Pharma presents novel sodium channel antagonists

Roche develops new inhibitors of tyrosine-protein kinase BTK

Novel phosphodiesterase 9A inhibitors reported

Celgene completes acquisition

NeuroTherapeutics Pharma divulges new GABA(A) receptor antagonists

Researchers in U.S. design new therapeutics for radiation injury

Benitec Biopharma enters into new licensing agreement

University of Dundee and GSK to target neglected parasitic diseases

Apexigen grants license for APX-004 development in China

Viral Genetics submits pre-IND for Lyme disease treatment

Gene-modified stem cell therapy shows promise to combat HIV infection

Study of AEZS-130 in cancer cachexia begins

Thrombotech clear to test THR-18 in U.S.

Apogenix's phase II trial in glioblastoma multiforme meets primary endpoint

Repligen submits MAA for SecreFlo

Recombinant protein therapy active against HIV in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...